During the corresponding time, Supernus Pharmaceuticals Inc recorded a revenue increase by 32.4 % year on year, sequentially revenue grew by 5.47 %. While revenue at the Supernus Pharmaceuticals Inc 's corporate clients
Supernus Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company develops and commercializes medicines for central nervous system (CNS) diseases. Its commercial products include Qelbree, approved for treating attention deficit hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 and adults, and GOCOVRI, approved for treating dyskinesia and "OFF" episodes in Parkinson's disease patients receiving levodopa-based therapy. The company employs dedicated sales and marketing resources in the U.S. to support revenue growth of its key marketed products. It also pursues strategic business development opportunities such as in-licensing, co-promotion, co-development partnerships, and acquisitions. The company serves market segments including pediatric and adult ADHD patients and Parkinson's disease patients experiencing dyskinesia and "OFF" episodes. Customers and markets referenced include Sage Therapeutics, Inc. and Sage Therapeutics, LLC.
In the realm of mental health, awareness is an empowering tool. From celebrities to everyday individuals, the narratives around conditions like Attention Deficit Hyperactivity Disorder (ADHD) are being shared more openly, paving the way for understanding, acceptance, and support. One such enlightening endeavor is the new video content series launched by Jay Glazer and his wife, Rosie Glazer, in partnership with Supernus Pharmaceuticals. This collaborative effort aims to shed light on the profound effects ADHD can have on relationships, while highlighting the positive role Qelbree can play in symptom management.Jay Glazer, renowned sports analyst and vibrant personality, openly discusses his experiences with ...
In a significant development within the field of neurology, Supernus Pharmaceuticals, Inc. has announced the resubmission of its New Drug Application (NDA) for SPN-830, an innovative apomorphine infusion device aimed at providing continuous treatment for motor fluctuations in patients with Parkinson s disease (PD). This announcement, made on August 1, 2024, highlights Supernus s commitment to improving therapeutic options for a condition that currently affects millions of individuals worldwide.Parkinson s disease is a progressive neurodegenerative disorder characterized by motor symptoms that include tremors, rigidity, and bradykinesia. One of the most debilitating aspects of PD is the OFF episodes that ca...
Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures, affects millions of individuals worldwide. Despite numerous available treatments, a significant percentage of patients continue to suffer from uncontrolled seizures, highlighting the dire need for new therapeutic avenues. Supernus Pharmaceuticals, Inc., a company renowned for its innovative approach to neurological and psychiatric diseases, has recently announced promising interim data from its ongoing open-label Phase 2a study of SPN-817, their novel, highly selective acetylcholinesterase (AChE) inhibitor. Unveiling SPN-817: A Novel Approach in Epilepsy TreatmentSPN-817 represents a significant advancement in epilepsy treatme...
Supernus Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company develops and commercializes medicines for central nervous system (CNS) diseases. Its commercial products include Qelbree, approved for treating attention deficit hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 and adults, and GOCOVRI, approved for treating dyskinesia and "OFF" episodes in Parkinson's disease patients receiving levodopa-based therapy. The company employs dedicated sales and marketing resources in the U.S. to support revenue growth of its key marketed products. It also pursues strategic business development opportunities such as in-licensing, co-promotion, co-development partnerships, and acquisitions. The company serves market segments including pediatric and adult ADHD patients and Parkinson's disease patients experiencing dyskinesia and "OFF" episodes. Customers and markets referenced include Sage Therapeutics, Inc. and Sage Therapeutics, LLC.
Sources:
Supernus Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Supernus Pharmaceuticals inc’s corporate clients.
For your research, we’ve provided 9 tables on Supernus Pharmaceuticals inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
144.47 %